Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05551117 · OUTCOME

Part 1: Mean Best Tumor Size Change Over Time

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors · Source last updated 2026-02-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percent change from baseline
Interval / dispersion
Standard Deviation
Time frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

Analysis population: All participants with mCRPC who received at least one dose of study treatment and had RECIST-evaluable disease per PCWG3 (Tumor Response Evaluable Population) in Part 1 of the study. Participants in Part 2 of the study did not have mCRPC and are excluded from this analysis.

Groups in this outcome

Part 1: MGC018 2.0 mg (Arm A)

vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks

Part 1: MGC018 2.7 mg (Arm B)

vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks

Part 1: Control Arm

abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.

Part 2

vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: MGC018 2.0 mg (Arm A)59
Part 1: MGC018 2.7 mg (Arm B)49
Part 1: Control Arm2
Part 20

Reported measurements

Source class 1
Values in percent change from baseline · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Part 1: MGC018 2.0 mg (Arm A)-13.059.70Not reportedNot reportedNot reported
Part 1: MGC018 2.7 mg (Arm B)-29.033.92Not reportedNot reportedNot reported
Part 1: Control Arm-7.447.16Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        59.70
        value
        -13.0
      2. group Id
        OG001
        spread
        33.92
        value
        -29.0
      3. group Id
        OG002
        spread
        7.16
        value
        -7.44
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    2. group Id
      OG001
      value
      49
    3. group Id
      OG002
      value
      2
    4. group Id
      OG003
      value
      0
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks
    id
    OG000
    title
    Part 1: MGC018 2.0 mg (Arm A)
  2. description
    vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks
    id
    OG001
    title
    Part 1: MGC018 2.7 mg (Arm B)
  3. description
    abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.
    id
    OG002
    title
    Part 1: Control Arm
  4. description
    vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks
    id
    OG003
    title
    Part 2
param Type
MEAN
population Description
All participants with mCRPC who received at least one dose of study treatment and had RECIST-evaluable disease per PCWG3 (Tumor Response Evaluable Population) in Part 1 of the study. Participants in Part 2 of the study did not have mCRPC and are excluded from this analysis.
reporting Status
POSTED
time Frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
title
Part 1: Mean Best Tumor Size Change Over Time
type
SECONDARY
unit Of Measure
percent change from baseline

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice